Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2007-4-2
pubmed:abstractText
Aberrant constitutive expression of c-Rel, p65 and p50 NF-kappaB subunits has been reported in over 90% of breast cancers. Recently, we characterized a de novo RelB NF-kappaB subunit synthesis pathway, induced by the cytomegalovirus (CMV) IE1 protein, in which binding of p50-p65 NF-kappaB and c-Jun-Fra-2 AP-1 complexes to the RELB promoter work in synergy to potently activate transcription. Although RelB complexes were observed in mouse mammary tumours induced by either ectopic c-Rel expression or carcinogen exposure, little is known about RelB in human breast disease. Here, we demonstrate constitutive de novo RelB synthesis is selectively active in invasive oestrogen receptor alpha (ERalpha)-negative breast cancer cells. ERalpha signalling reduced levels of functional NF-kappaB and Fra-2 AP-1 and inhibited de novo RelB synthesis, leading to an inverse correlation between RELB and ERalpha gene expression in human breast cancer tissues and cell lines. Induction of Bcl-2 by RelB promoted the more invasive phenotype of ERalpha-negative cancer cells. Thus, inhibition of de novo RelB synthesis represents a new mechanism whereby ERalpha controls epithelial to mesenchymal transition (EMT).
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-11325857, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-11704864, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-12086865, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-12438279, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-12490681, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-12705869, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-12897145, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-14613549, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-15184680, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-15208657, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-15265917, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-15314694, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-15367686, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-15596805, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-15721472, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-15734144, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-16205698, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-16260626, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-16510574, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-16723991, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-16740744, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-16982684, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-17401385, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-1835668, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-7614468, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-7845467, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-8219249, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-8314777, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-9199297, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-9205050, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-9399940, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-9658402, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-9699869, http://linkedlifedata.com/resource/pubmed/commentcorrection/17369819-9727009
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1465-7392
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
470-8
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:17369819-Animals, pubmed-meshheading:17369819-Blotting, Northern, pubmed-meshheading:17369819-Breast Neoplasms, pubmed-meshheading:17369819-Cell Line, Tumor, pubmed-meshheading:17369819-Cell Movement, pubmed-meshheading:17369819-Cell Transformation, Neoplastic, pubmed-meshheading:17369819-Electrophoretic Mobility Shift Assay, pubmed-meshheading:17369819-Estrogen Receptor alpha, pubmed-meshheading:17369819-Estrogens, pubmed-meshheading:17369819-Female, pubmed-meshheading:17369819-Fos-Related Antigen-2, pubmed-meshheading:17369819-Gene Expression Regulation, Neoplastic, pubmed-meshheading:17369819-Humans, pubmed-meshheading:17369819-Immunoblotting, pubmed-meshheading:17369819-Mice, pubmed-meshheading:17369819-Microscopy, Fluorescence, pubmed-meshheading:17369819-NF-kappa B, pubmed-meshheading:17369819-Phenotype, pubmed-meshheading:17369819-Protein Binding, pubmed-meshheading:17369819-Proto-Oncogene Proteins c-bcl-2, pubmed-meshheading:17369819-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:17369819-Signal Transduction, pubmed-meshheading:17369819-Transcription Factor RelB
pubmed:year
2007
pubmed:articleTitle
Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2.
pubmed:affiliation
Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA.
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural